Peter Quarg

1.5k total citations · 1 hit paper
13 papers, 1.0k citations indexed

About

Peter Quarg is a scholar working on Pharmacology, Physiology and Psychiatry and Mental health. According to data from OpenAlex, Peter Quarg has authored 13 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pharmacology, 5 papers in Physiology and 5 papers in Psychiatry and Mental health. Recurrent topics in Peter Quarg's work include Cholinesterase and Neurodegenerative Diseases (7 papers), Alzheimer's disease research and treatments (5 papers) and Dementia and Cognitive Impairment Research (5 papers). Peter Quarg is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (7 papers), Alzheimer's disease research and treatments (5 papers) and Dementia and Cognitive Impairment Research (5 papers). Peter Quarg collaborates with scholars based in Switzerland, United States and Sweden. Peter Quarg's co-authors include Sibel Tekin, Andrew Lees, Alberto Albanese, Dag Aarsland, Werner Poewe, Günther Deuschl, Franck Durif, Teus van Laar, Erik Ch. Wolters and Roger Lane and has published in prestigious journals such as New England Journal of Medicine, Neurobiology of Aging and Alzheimer s & Dementia.

In The Last Decade

Peter Quarg

13 papers receiving 981 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rivastigmine for Dementia Associated with Parkinson's Disease

2004 793 citations Murat Emre, Dag Aarsland et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Quarg Switzerland	7	580	383	249	226	165	13	1.0k
Alain Robillard Canada	14	634 1.1×	536 1.4×	190 0.8×	232 1.0×	268 1.6×	18	1.4k
A. Cicin-Sain Switzerland	6	442 0.8×	539 1.4×	289 1.2×	255 1.1×	145 0.9×	6	1.1k
Sabiha Jabeen United Kingdom	8	285 0.5×	357 0.9×	111 0.4×	237 1.0×	142 0.9×	8	761
Chanoch Miodownik Israel	20	317 0.5×	402 1.0×	134 0.5×	129 0.6×	49 0.3×	43	1.1k
Neda Minakaran United Kingdom	7	122 0.2×	378 1.0×	282 1.1×	326 1.4×	97 0.6×	19	1.1k
Simon Vann Jones United Kingdom	6	205 0.4×	207 0.5×	68 0.3×	198 0.9×	56 0.3×	9	611
Mark Versavel United States	13	422 0.7×	301 0.8×	289 1.2×	691 3.1×	154 0.9×	21	1.2k
Raymond Levy United Kingdom	11	129 0.2×	395 1.0×	126 0.5×	275 1.2×	160 1.0×	23	742
Tsuneyoshi Ota Japan	14	137 0.2×	188 0.5×	198 0.8×	243 1.1×	117 0.7×	25	696
Gustavo Alva United States	15	82 0.1×	346 0.9×	233 0.9×	204 0.9×	191 1.2×	37	957

Countries citing papers authored by Peter Quarg

Since Specialization

Citations

This map shows the geographic impact of Peter Quarg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Quarg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Quarg more than expected).

Fields of papers citing papers by Peter Quarg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Quarg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Quarg. The network helps show where Peter Quarg may publish in the future.

Co-authorship network of co-authors of Peter Quarg

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Quarg. A scholar is included among the top collaborators of Peter Quarg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Quarg. Peter Quarg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Graf, Ana, Marie‐Emmanuelle Riviere, Fonda Liu, et al.. (2020). Umibecestat in the API Generation program: Worsening in RBANS and/or CDR on treatment reverses after wash‐out. Alzheimer s & Dementia. 16(S9). 6 indexed citations

Ocampo, Alex, et al.. (2019). Identifying Treatment Effects using Trimmed Means when Data are Missing Not at Random. arXiv (Cornell University). 3 indexed citations

Akacha, Mouna, et al.. (2019). Estimands in a Chronic Pain Trial: Challenges and Opportunities. Statistics in Biopharmaceutical Research. 12(1). 39–44. 14 indexed citations

Vandemeulebroecke, Marc, Björn Bornkamp, Tillmann Krahnke, et al.. (2017). A Longitudinal Item Response Theory Model to Characterize Cognition Over Time in Elderly Subjects. CPT Pharmacometrics & Systems Pharmacology. 6(9). 635–641. 16 indexed citations

Graf, Ana, Niels Andreasen, Martin R. Farlow, et al.. (2012). P1‐214: Long‐term administration of active immunotherapy CAD106 in phase IIa open‐label extension studies in Alzheimer's disease patients. Alzheimer s & Dementia. 8(4S_Part_5). 1 indexed citations

Winblad, Bengt, Martin R. Farlow, Kaj Blennow, et al.. (2011). P2‐083: Aβ‐specific antibodies induced by active immunotherapy CAD106 engage Aβ in plasma in AD patients. Alzheimer s & Dementia. 7(4S_Part_10). 3 indexed citations

Graf, Ana, Niels Andreasen, Marie‐Emmanuelle Riviere, et al.. (2010). P3‐275: Optimization of the treatment regimen with active Aß immunotherapy CAD106 in alzheimer patients. Alzheimer s & Dementia. 6(4S_Part_17). 2 indexed citations

Small, G. W., Daniel Kaufer, Marta S. Mendiondo, Peter Quarg, & René Spiegel. (2005). Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. International Journal of Clinical Practice. 59(4). 473–477. 70 indexed citations

Farlow, Martin R., Gary W. Small, Peter Quarg, & Andreas Krause. (2005). Efficacy of Rivastigmine in Alzheimer’s Disease Patients with Rapid Disease Progression: Results of a Meta-Analysis. Dementia and Geriatric Cognitive Disorders. 20(2-3). 192–197. 42 indexed citations

10.

Emre, Murat, Dag Aarsland, Alberto Albanese, et al.. (2004). Rivastigmine for Dementia Associated with Parkinson's Disease. New England Journal of Medicine. 351(24). 2509–2518. 793 indexed citations breakdown →

11.

Burns, Alistair, René Spiegel, & Peter Quarg. (2004). Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry. 19(3). 243–249. 48 indexed citations

12.

Kurz, Alexander, Martin R. Farlow, Peter Quarg, & René Spiegel. (2004). Disease Stage in Alzheimer Disease and Treatment Effects of Rivastigmine. Alzheimer Disease & Associated Disorders. 18(3). 123–128. 43 indexed citations

13.

Emre, Murat, Marco Onofrj, Sibel Tekin, Peter Quarg, & Roger Lane. (2004). O1-05-03 Benefits of rivastigmine in Parkinson's disease dementia: results from the express study. Neurobiology of Aging. 25. S19–S19. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact